News & Updates
Filter by Specialty:
Can very low-risk breast cancer patients be spared from postop radiotherapy?
Adjuvant radiotherapy (RT) may be omitted in women with very low-risk breast cancer who have had breast conserving surgery (BCS) and have been receiving endocrine therapy, according to findings from the LUMINA study.
Can very low-risk breast cancer patients be spared from postop radiotherapy?
12 Jul 2022
Sabizabulin for metastatic castration-resistant prostate cancer clears phase early trial
The oral cytoskeleton disruptor sabizabulin shows antitumour activity in men with metastatic castration-resistant prostate cancer, while having a favourable safety profile, as shown in the results of a phase Ib/II trial.
Sabizabulin for metastatic castration-resistant prostate cancer clears phase early trial
10 Jul 2022
Triplet regimen works against triple-negative breast cancer
Treatment with a novel combination of famitinib, camrelizumab, and nab-paclitaxel appears safe and effective in patients with advanced immunomodulatory triple-negative breast cancer (TNBC), as shown in the results of the phase II FUTURE-C-Plus trial.
Triplet regimen works against triple-negative breast cancer
08 Jul 2022
Age the biggest risk factor for COVID-19 mortality in haematological cancer patients
A study conducted in England has shown that in patients with haematological malignancy, the risk of COVID-19–related mortality is greatly influenced by age.
Age the biggest risk factor for COVID-19 mortality in haematological cancer patients
07 Jul 2022
L-MOCA: Olaparib maintenance for ovarian cancer benefits Asians
Maintenance monotherapy with olaparib appears safe and effective in Asian patients with platinum-sensitive relapsed (PSR) ovarian cancer, regardless of their BRCA status, as shown in the results of the phase III, open-label, single-arm L-MOCA study.
L-MOCA: Olaparib maintenance for ovarian cancer benefits Asians
07 Jul 2022
Post-transplant KRd a new SoC for MM?
In the ongoing phase III ATLAS study evaluating patients with newly diagnosed multiple myeloma (MM), progression-free survival (PFS) was better with maintenance treatment with carfilzomib, lenalidomide, and dexamethasone (KRd) than lenalidomide (R) alone after autologous stem-cell transplantation (ASCT).